Oppenheimer Asset Management Inc. Buys 4,060 Shares of Apellis Pharmaceuticals, Inc. (NASDAQ:APLS)

Oppenheimer Asset Management Inc. increased its position in Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) by 46.7% during the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 12,754 shares of the company’s stock after purchasing an additional 4,060 shares during the period. Oppenheimer Asset Management Inc.’s holdings in Apellis Pharmaceuticals were worth $489,000 at the end of the most recent reporting period.

Several other institutional investors also recently bought and sold shares of APLS. Vanguard Personalized Indexing Management LLC purchased a new position in Apellis Pharmaceuticals in the fourth quarter worth about $281,000. Norges Bank purchased a new stake in Apellis Pharmaceuticals during the 4th quarter valued at $56,640,000. Assetmark Inc. raised its stake in shares of Apellis Pharmaceuticals by 52.6% in the fourth quarter. Assetmark Inc. now owns 17,344 shares of the company’s stock worth $1,038,000 after purchasing an additional 5,975 shares during the last quarter. Franklin Resources Inc. bought a new position in shares of Apellis Pharmaceuticals during the fourth quarter valued at $13,755,000. Finally, Steward Partners Investment Advisory LLC boosted its position in shares of Apellis Pharmaceuticals by 21.4% during the fourth quarter. Steward Partners Investment Advisory LLC now owns 29,800 shares of the company’s stock valued at $1,784,000 after buying an additional 5,250 shares during the last quarter. 96.29% of the stock is owned by hedge funds and other institutional investors.

Apellis Pharmaceuticals Stock Down 11.5 %

APLS stock opened at $32.51 on Friday. The business’s 50-day moving average price is $37.87 and its 200-day moving average price is $43.78. The stock has a market cap of $3.95 billion, a P/E ratio of -9.40 and a beta of 0.88. Apellis Pharmaceuticals, Inc. has a twelve month low of $31.00 and a twelve month high of $73.80. The company has a quick ratio of 4.18, a current ratio of 5.08 and a debt-to-equity ratio of 1.73.

Apellis Pharmaceuticals (NASDAQ:APLS) last posted its quarterly earnings results on Thursday, August 1st. The company reported ($0.30) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.33) by $0.03. The business had revenue of $199.70 million during the quarter, compared to analyst estimates of $190.89 million. Apellis Pharmaceuticals had a negative net margin of 52.99% and a negative return on equity of 138.32%. The company’s revenue was up 110.2% on a year-over-year basis. During the same period in the prior year, the business posted ($1.02) earnings per share. On average, equities research analysts forecast that Apellis Pharmaceuticals, Inc. will post -1.29 EPS for the current year.

Insider Activity at Apellis Pharmaceuticals

In other Apellis Pharmaceuticals news, Director A. Sinclair Dunlop sold 37,000 shares of the stock in a transaction on Monday, September 16th. The stock was sold at an average price of $36.23, for a total value of $1,340,510.00. Following the completion of the sale, the director now owns 100,000 shares in the company, valued at approximately $3,623,000. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. 6.80% of the stock is owned by corporate insiders.

Wall Street Analyst Weigh In

A number of equities analysts have weighed in on APLS shares. UBS Group decreased their target price on Apellis Pharmaceuticals from $85.00 to $83.00 and set a “buy” rating for the company in a research report on Friday, August 9th. Mizuho cut their target price on shares of Apellis Pharmaceuticals from $42.00 to $39.00 and set a “neutral” rating for the company in a research report on Friday. HC Wainwright lowered their price target on Apellis Pharmaceuticals from $92.00 to $83.00 and set a “buy” rating on the stock in a report on Friday, August 2nd. Wedbush lifted their price objective on Apellis Pharmaceuticals from $38.00 to $41.00 and gave the stock a “neutral” rating in a report on Friday, August 9th. Finally, The Goldman Sachs Group increased their target price on Apellis Pharmaceuticals from $66.00 to $74.00 and gave the company a “buy” rating in a report on Friday, August 9th. Four analysts have rated the stock with a hold rating, ten have given a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $70.80.

Apellis Pharmaceuticals Profile

Apellis Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA).